TWA
PMVP icon

TCI Wealth Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

TCI Wealth Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-591
Closed -$2.82K – 1681
2023
Q1 		$2.82K Buy
+591
New +$4.16K ﹤0.01% 1879
2022
Q1 		– Sell
-182
Closed -$4K – 2396
2021
Q4 		$4K Buy
+182
New +$4.4K ﹤0.01% 1873

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCI Wealth Advisors's PMVP Position: Q2 2023 in Review

TCI Wealth Advisors sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 591 shares — an estimated $2.82K sold.

TCI Wealth Advisors first reported a position in PMVP in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q4 2021. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

  • TCI Wealth Advisors reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 591 PMV Pharmaceuticals shares in Q2 2023, an estimated $2.82K.
  • TCI Wealth Advisors first reported a position in PMV Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's PMV Pharmaceuticals position peaked at $4K in Q4 2021.
  • 106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.